Scaling N-of-1 Therapies To Viability RARECast podcast

Artwork

Health Industry Business Health Care Rare Disease RARECast Health and Well-Being

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

RARECast « »
Scaling N-of-1 Therapies to Viability

2M ago 31:32

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

The work of Boston Children’s Hospital’s Timothy Yu to develop a customized antisense oligonucleotide to treat Mila, a child with an ultra-rare neurodegenerative disease, created much excitement for the potential of N-of-1 therapies. Julia Vitarello, Mila’s mother, has talked about going from Mila to millions and co-founded EveryONE Medicines to enable the development of individualized therapies on a large scale. Earlier this year the company named industry veteran Kent Rogers as its CEO. We spoke to Rogers about the challenges of building a sustainable business model for the development of individualized therapies, the regulatory hurdles it may face, and what it will take to get payers to embrace such medicines.

… continue reading

520 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Artwork

Scaling N-of-1 Therapies to Viability

28 subscribers

published 2M ago

Del

MP3•Episode hjem

Indhold leveret af RARECast. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af RARECast eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

The work of Boston Children’s Hospital’s Timothy Yu to develop a customized antisense oligonucleotide to treat Mila, a child with an ultra-rare neurodegenerative disease, created much excitement for the potential of N-of-1 therapies. Julia Vitarello, Mila’s mother, has talked about going from Mila to millions and co-founded EveryONE Medicines to enable the development of individualized therapies on a large scale. Earlier this year the company named industry veteran Kent Rogers as its CEO. We spoke to Rogers about the challenges of building a sustainable business model for the development of individualized therapies, the regulatory hurdles it may face, and what it will take to get payers to embrace such medicines.

… continue reading

520 episoder

#Health Industry #Business #Health Care #Rare Disease #RARECast #Health and Well-Being

Все серии

×

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

Lyt til 500+ emner